SAFE, PRIVATE & SECURE
Your iOPharma™ account is password protected and safe from prying eyes. All iOPharma™ plans include SSL security - the same as online banks. Your data is secure.
SUPPORT FOR MULTIPLE LANGUAGES
iOPharma™ will be translated into Chinese, Spanish, French, German and Portuguese. More languages will be added to this list as time goes on. To find out more about the translations, please contact us at info@io-pharma.com.
FREE REGISTRATION
Whether you’re a buyer or a supplier the iOPharma™ platform will benefit your organisation.
REGISTER NOW
Fire in the Blood – review
A hard hitting documentary tells the story of how big pharma blocked millions of world's poorest...
Read moreGSK to stop paying doctors to make speeches
GlaxoSmithKline (GSK) is making major changes to its incentive schemes following a damaging...
Read moreBenefits of statin therapy may extend beyond lowering lipids
People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques...
Read moreForeign Materials in Pharmaceuticals
Despite the best efforts of manufacturers to produce to the highest standards, there are a number...
Read more1500 Foreign Materials Identified
RSSL's microscopy laboratory is anticipating its 1500th foreign material identification project of...
Read moreFDA pain market moves 'creating huge opportunities'
The US opioid market is dominated by non tamper-resistant formulations, but the Food and Drug...
Read moreGSK to end payments to doctors
Early next year, GlaxoSmithKline (GSK) will begin a consultation on ending direct payments to...
Read moreDrug cuts breast cancer cases
Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal...
Read moreNovartis' panobinostat impresses in myeloma trial
Novartis has posted promising late-stage data on a new treatment for multiple myeloma which shows...
Read more1500 Foreign Materials Identified
RSSL's microscopy laboratory is anticipating its 1500th foreign material identification project of...
Read more